Human sarcomas are a heterogeneous group of over 50 different malignant tumors for which very few diagnostic markers currently exist. MicroRNA (miRNA) transcript levels have been proposed for use in ...

While sarcomas can be divided into soft-tissue or bone sarcomas, there are about 600 different types of sarcomas patients can be diagnosed with. Liposarcomas — Tumors that arise from cells of fat ...

In soft tissue sarcomas, the diagnosis of malignant fibrous histiocytoma (MFH) has been a very controversial issue, and MFH is now considered to be reclassified into pleomorphic subtypes of other ...

An existing cancer immunotherapy drug reduces tumor size in some types of rare connective tissue cancers, called sarcomas. Additional analyses of tumor biopsies and blood samples, which will help the ...

Even in the public health shadows of the more common cancers like breast cancer, for the few but strong patients with a sarcoma diagnosis, we are obligated to spread awareness, restore hope and with ...

Soft tissue sarcomas are cancers that develop in your body’s soft tissues like muscle, fat, tendons, or cartilage. Your legs are the most common place they develop. The American Cancer Society ...

As a study in Clinical Diabetes and Endocrinology points out, Kaposi lesions may be less visible in people who have darker skin tones. Although Kaposi lesions can be asymptomatic, they may sometimes ...

Sarcomas are tumors that form in the body’s connective tissues such as bone, muscle and fat. They are rare and, because there are more than 150 types, patients benefit from seeing a sarcoma specialist ...

Uterine cancer develops in the tissues of the uterus, the hollow organ in the pelvis where a fetus could grow and develop during pregnancy. There are two main types of uterine cancer. The most common ...

The uterus is pear shaped with the narrow end pointing down. This narrow lower end, which extends into the vagina, is the cervix. The wider upper part is the body of the uterus, or the uterine corpus.

Sonnet BioTherapeutics Holdings, Inc. has announced an expansion of its Phase 1 SB101 clinical trial of SON-1010, a candidate immunotherapy, to evaluate its effectiveness in combination with the ...